Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
HCWB | US
-0.04
-6.67%
Healthcare
Biotechnology
30/06/2024
17/10/2024
0.56
0.59
0.59
0.55
HCW Biologics Inc. a clinical-stage biopharmaceutical company focuses on discovering and developing novel immunotherapies for chronic low-grade inflammation and age-related diseases. The company's lead products include HCW9218 which is an injectable immunotherapeutic for patients with pancreatic ovarian breast prostate and colorectal cancers as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases such as alopecia areata and metabolic diseases. It also develops HCW9201 a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar Florida.
View LessLow Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
148.6%1 month
148.4%3 months
138.0%6 months
116.8%-
-
2.80
-1.59
0.37
-3.63
7.21
-
-36.58M
21.18M
21.18M
-
-2.24K
-
-0.60
-344.32
0.87
0.14
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.21
Range1M
0.27
Range3M
0.30
Rel. volume
0.73
Price X volume
9.93K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
BioXcel Therapeutics Inc | BTAI | Biotechnology | 0.57 | 23.22M | -1.72% | n/a | -139.46% |
ImmunoCellular Therapeutics Ltd | IMUC | Biotechnology | 0.138 | 23.09M | 0.00% | 0.02 | -82.78% |
Aligos Therapeutics Inc | ALGS | Biotechnology | 7.21 | 23.04M | -2.30% | n/a | 14.63% |
Cyclo Therapeutics Inc | CYTH | Biotechnology | 0.7849 | 22.52M | -0.65% | n/a | -58.50% |
Pieris Pharmaceuticals Inc | PIRS | Biotechnology | 16.93 | 22.08M | 2.67% | n/a | 0.00% |
NeuroSense Therapeutics Ltd. Ordinary Shares | NRSN | Biotechnology | 1.1 | 21.79M | 12.30% | n/a | -2.11% |
Spruce Biosciences Inc | SPRB | Biotechnology | 0.51 | 21.06M | -1.75% | n/a | 6.24% |
Cocrystal Pharma Inc | COCP | Biotechnology | 2.04 | 20.75M | -7.27% | n/a | 10.24% |
Matinas BioPharma Holdings Inc | MTNB | Biotechnology | 4.08 | 20.66M | 4.88% | n/a | 16.97% |
BIOR | BIOR | Biotechnology | 0.5538 | 20.20M | -6.14% | n/a | -52.57% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.63 | 0.53 | Cheaper |
Ent. to Revenue | 7.21 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 2.80 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 137.96 | 72.92 | Riskier |
Debt to Equity | -1.59 | -1.24 | Cheaper |
Debt to Assets | 0.37 | 0.25 | Expensive |
Market Cap | 21.18M | 3.78B | Emerging |